The remarkable spectrum of methotrexate toxicities.
This article outlines a general scheme for categorizing medication-related adverse events. This is followed by a review of the less well-recognized adverse events attributed to low-dose methotrexate therapy. Known and suspected risk factors are described and causative mechanisms are suggested. Ultimately, this article aims at increasing the readers awareness of uncommon or underreported methotrexate-associated adverse events so that prescribing and monitoring practices can be tailored to enhance the safe use of this valuable antirheumatic agent.
McKendry
R J
RJ
Department of Medicine, University of Ottawa, Ontario, Canada.
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D001847:Bone Diseases / Q000139:chemically induced; D002490:Central Nervous System / Q000187:drug effects / Q000473:pathology; D004064:Digestive System / Q000187:drug effects / Q000473:pathology; D006402:Hematologic Diseases / Q000139:chemically induced; D006710:Homocysteine / Q000097:blood; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects* / Q000493:pharmacokinetics; D012218:Rheumatoid Nodule / Q000139:chemically induced
D018501:Antirheumatic Agents; D006710:Homocysteine; D008727:Methotrexate